Structural Heart Disease

Drawing of the heart that shows areas affected by structural heart defects

Structural Heart Disease Management

Transcatheter and surgical solutions

More than 71,000 children in the U.S. and European Union combined are born with structural heart defects each year.1,2 In addition, many adults worldwide battle conditions such as valvular disease and aortic stenosis, the narrowing of the aortic valve. In fact, aortic stenosis is the world’s most common noncongenital valve disease3 and the third most common cardiovascular disease in the U.S.4 


Abbott offers surgical and transcatheter options for treating structural heart disease. We are focused on improving the lives of patients and offering physicians like you products designed for ease of use and that have proven clinical outcomes.5,6



Surgical Heart Valve Replacement Portfolio

We are advancing surgical replacement technologies with our mechanical and tissue stented valves. Designed to mimic the function of a natural, healthy heart valve, our valves deliver superior hemodynamics and durability.

Related Portfolios

Learn about our other portfolio solution to help manage your patients’ structural heart disease.

Structural Heart Occlusion Portfolio

Our portfolio of minimally invasive, catheter-based structural heart occluders is built on proven AMPLATZER™ technology and designed to treat congenital heart defects. Our occluders feature flexible designs engineered for complete closure.

Celebrating Four Decades of Valve Innovation

As pioneers in heart valve technology, Abbott is an experienced mechanical valve company in the world with more than two million mechanical valves implanted worldwide to date. We offer catheter-based and surgical solutions—including market-leading mechanical and tissue stented heart valves designed for exceptional hemodynamics, durability and ease of implantation.

It’s part of the excitement of medicine to me. It’s bringing something new to the field.
—Dr. Robert Emery, Cardiovascular and Thoracic Surgeon


Watch this video to learn more about our innovations in heart valve technology.

Valvular Disease: The Next Cardiac Epidemic

According to an article in Heart, an international peer-reviewed journal for health professionals and researchers in all areas of cardiology, the prevalence of valvular heart disease is growing as life expectancy increases.3

Population statistics worldwide project an imminent increase in the elderly population—in the U.K., for example, there will be an estimated 4 million people aged between 75 and 84 by 2018, and the population beyond the age of 85 is set to double by 2028.7

Read the article.

Market-leading AMPLATZER™ structural heart occluders for transcatheter closure of heart defects

Industry-Leading Structural Heart Occluders

At Abbott, we invest in studies that demonstrate the safety, efficacy and cost-effectiveness of our transformative therapies. Backed by more than 17 years of clinical experience, our AMPLATZER™ occluders define a market-leading standard of care for transcatheter closure of heart defects.5,10,11

See the evidence

The latest addition to our structural heart occlusion portfolio, the AMPLATZER™ PFO Occluder revolutionizes the risk reduction of recurrent ischemic stroke in patients with PFOs. See the results from the RESPECT final analysis as presented at TCT 2106.


1. National Institutes of Health. What are congenital heart defects? Retrieved from 
2. Dolk, H., Loane, M., Game, E., & European Surveillance of Congenital Anomalies (EUROCAT) Working Group. (2011). Congenital heart defects in Europe: Prevalence and perinatal mortality, 2000 to 2005. Circulation, 123(8), 841-849.
3. Welt, F. G. P., Davidson, M. J., Leon, M. B., & Eisenhauer, A. C. (2011). Transcatheter aortic valve replacement. Circulation, 124, 2944-2948.
4. Maganti, K., Rigolin, V. H., Sarano, M. E., & Bonow, R. O. (2010). Valvular heart disease: Diagnosis and management. Mayo Clinic Proceedings, 85(5), 483-500.
5. Forbes, T. (2011, July). Interim results of the Amplatzer septal occluder post approval study. Presented at the meeting of the Pediatric and Adult Interventional Cardiac Symposium, Boston, MA. 
6. Bavaria, J. E., Desai, N. D., Cheung, A., Petracek, M. R., Groh, M. A., Borger, M. A., & Schaff, H. V. (2014). The St. Jude Medical Trifecta aortic pericardial valve: Results from the global, multicenter, prospective clinical study. Journal of Thoracic and Cardiovascular Surgery, 147(2), 590-597.
7. d'Arcy, J. L., Prendergast, B. D., Chambers, J. B., Ray, S. G., & Bridgewater, B. (2011). Valvular heart disease: The next cardiac epidemic. Heart, 97(2), 91-93.
8. Manoharan, G., & Portico, C. E. (2014, September). Trial Assessment of the St. Jude Medical Portico Transcatheter Aortic Valve Implant and the Transfemoral Delivery System. Presented at the meeting of the Transcatheter Cardiovascular Therapeutics, Washington, DC. 
9. Everett, A. D., Jennings, J., Sibinga, E., Owada, C., Lim, D. S., Cheatham, J., … Ringel, R. (2009).
Community use of the Amplatzer atrial septal defect occluder: Results of the multicenter MAGIC atrial septal defect study. Pediatric Cardiology, 30(3), 240-247.

Orange 24 surrounded by headset, represents "Place an order"

Contact Customer Service

Our customer service experts can help with your product orders or questions.